Matinas Biopharma Holdings, Inc. (MTNB) Financial Statements (2023 and Earlier)

Company Profile

Business Address 1545 ROUTE 206 SOUTH
BEDMINSTER, NJ 07921
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments49,62258,67927,77512,4477,3074,105
Cash and cash equivalents21,03012,43222,17012,4477,3074,105
Short-term investments28,59246,2475,605   
Restricted cash and investments50136250100155 
Prepaid expense   539502 
Other undisclosed current assets1,3212,7401,898  460
Total current assets:50,99361,55529,92313,0857,9644,565
Noncurrent Assets
Finance lease, right-of-use asset2258117
Operating lease, right-of-use asset4,2193,2773,761
Property, plant and equipment1,5381,5241,7492,0431,570356
Long-term investments and receivables    536541
Long-term investments    536541
Intangible assets, net (including goodwill)4,3544,3544,3544,3544,3544,354
Goodwill1,3361,3361,3361,3361,3361,336
Intangible assets, net (excluding goodwill)3,0173,0173,0173,0173,0173,017
Restricted cash and investments200200336461  
Total noncurrent assets:10,3339,41210,3176,8586,4605,251
TOTAL ASSETS:61,32670,96740,24019,94314,4249,816
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,7893,1452,6192,5571,5421,305
Accounts payable938350679296583476
Accrued liabilities2,8512,7951,9401,087959830
Interest and dividends payable   1,174  
Debt2131478283197128
Deferred revenue and credits48511
Other undisclosed current liabilities539391    
Total current liabilities:4,3493,5683,0972,8402,2251,445
Noncurrent Liabilities
Long-term debt and lease obligation4,1433,3283,7501086816
Finance lease, liability32455
Capital lease obligations1086816
Operating lease, liability4,1403,3043,696
Liabilities, other than long-term debt3413413418548481,205
Deferred rent credit   513
Deferred tax liabilities, net3418481,205
Deferred income tax liabilities341341341
Other undisclosed noncurrent liabilities    601 
Total noncurrent liabilities:4,4843,6694,0919621,5171,222
Total liabilities:8,8337,2377,1893,8023,7422,666
Stockholders' equity
Stockholders' equity attributable to parent, including:52,49363,73133,05216,14210,6827,150
Preferred stock 3,798   6,086
Common stock2220161196
Additional paid in capital184,251167,192113,42872,29556,23036,238
Accumulated other comprehensive income (loss)(145)228(1)   
Accumulated deficit(131,634)(107,507)(84,378)(65,945)(51,275)(35,180)
Other undisclosed stockholders' equity attributable to parent  3,9869,7805,717 
Total stockholders' equity:52,49363,73133,05216,14210,6827,150
TOTAL LIABILITIES AND EQUITY:61,32670,96740,24019,94314,4249,816

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues3315890120150 
Gross profit:3315890120150 
Operating expenses(24,768)(24,365)(19,011)(14,766)(16,652)(8,257)
Operating loss:(24,735)(24,207)(18,921)(14,647)(16,502)(8,257)
Nonoperating income (expense)1,4511,7605415722(17)
Investment income, nonoperating1,3281,0731,007 637675
Debt instrument, convertible, beneficial conversion feature     4,394
Other nonoperating income123686    
Interest and debt expense(3)(7)(12)(13) (1)
Loss from continuing operations before income taxes:(23,286)(22,454)(18,392)(14,603)(16,480)(8,275)
Income tax benefit   507357 
Loss before gain (loss) on sale of properties:(23,286)(22,454)(18,392)(14,096)(16,123)(8,275)
Other undisclosed net income46,586     
Net income (loss):23,300(22,454)(18,392)(14,096)(16,123)(8,275)
Other undisclosed net income (loss) attributable to parent(46,583)71,01913637676
Net loss attributable to parent:(23,283)(22,447)(17,373)(14,083)(15,486)(7,599)
Preferred stock dividends and other adjustments(396) (339)(905) (4,394)
Other undisclosed net loss available to common stockholders, basic (793)(586) (17,350) 
Net loss available to common stockholders, diluted:(23,679)(23,240)(18,297)(14,988)(32,836)(11,993)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):23,300(22,454)(18,392)(14,096)(16,123)(8,275)
Other comprehensive income (loss)(374)229(1)   
Comprehensive income (loss):22,926(22,224)(18,393)(14,096)(16,123)(8,275)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(46,583)71,019   
Comprehensive loss, net of tax, attributable to parent:(23,657)(22,218)(17,374)(14,096)(16,123)(8,275)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: